• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

淋巴结仿生支架增强CAR-T疗法对实体瘤的疗效。

Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor.

作者信息

Liao Ziyan, Jiang Jie, Wu Wei, Shi Jiaqi, Wang Yanfang, Yao Yuejun, Sheng Tao, Liu Feng, Liu Wei, Zhao Peng, Lv Feifei, Sun Jie, Li Hongjun, Gu Zhen

机构信息

National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

出版信息

Natl Sci Rev. 2024 Jan 11;11(4):nwae018. doi: 10.1093/nsr/nwae018. eCollection 2024 Apr.

DOI:10.1093/nsr/nwae018
PMID:38440217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10911814/
Abstract

The limited infiltration and persistence of chimeric antigen receptor (CAR)-T cells is primarily responsible for their treatment deficits in solid tumors. Here, we present a three-dimensional scaffold, inspired by the physiological process of T-cell proliferation in lymph nodes. This scaffold gathers the function of loading, delivery, activation and expansion for CAR-T cells to enhance their therapeutic effects on solid tumors. This porous device is made from poly(lactic-co-glycolic acid) by a microfluidic technique with the modification of T-cell stimulatory signals, including anti-CD3, anti-CD28 antibodies, as well as cytokines. This scaffold fosters a 50-fold CAR-T cell expansion and a 15-fold cell expansion . Particularly, it maintains long-lasting expansion of CAR-T cells for up to 30 days in a cervical tumor model and significantly inhibits the tumor growth. This biomimetic delivery strategy provides a versatile platform of cell delivery and activation for CAR-T cells in treating solid tumors.

摘要

嵌合抗原受体(CAR)-T细胞的有限浸润和持久性是其在实体瘤治疗中存在缺陷的主要原因。在此,我们展示了一种受淋巴结中T细胞增殖生理过程启发的三维支架。该支架具备CAR-T细胞的负载、递送、激活和扩增功能,以增强其对实体瘤的治疗效果。这种多孔装置由聚乳酸-乙醇酸共聚物通过微流控技术制成,并修饰了T细胞刺激信号,包括抗CD3、抗CD28抗体以及细胞因子。该支架促进CAR-T细胞扩增50倍以及细胞扩增15倍。特别地,在宫颈癌模型中,它能使CAR-T细胞持续扩增长达30天,并显著抑制肿瘤生长。这种仿生递送策略为CAR-T细胞治疗实体瘤提供了一个通用的细胞递送和激活平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/00f7c4796aea/nwae018fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/3f6cdfae9bdd/nwae018fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/961c82e1861b/nwae018fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/4f93fb37175d/nwae018fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/00f7c4796aea/nwae018fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/3f6cdfae9bdd/nwae018fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/961c82e1861b/nwae018fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/4f93fb37175d/nwae018fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1457/10911814/00f7c4796aea/nwae018fig4.jpg

相似文献

1
Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor.淋巴结仿生支架增强CAR-T疗法对实体瘤的疗效。
Natl Sci Rev. 2024 Jan 11;11(4):nwae018. doi: 10.1093/nsr/nwae018. eCollection 2024 Apr.
2
Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors.含二甲双胍的水凝胶支架增强 CAR-T 疗法治疗术后实体瘤。
Biomaterials. 2023 Apr;295:122052. doi: 10.1016/j.biomaterials.2023.122052. Epub 2023 Feb 15.
3
Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice.共输注表达趋化因子和共刺激配体的 aAPCs 与 CAR T 细胞可增强小鼠的抗肿瘤疗效。
Cancer Lett. 2023 Aug 1;568:216287. doi: 10.1016/j.canlet.2023.216287. Epub 2023 Jun 30.
4
Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.4-1BB 配体与 PD-1 检查点抑制剂交联的分泌增强嵌合抗原受体 T 细胞实体瘤疗效。
Hum Gene Ther. 2023 Nov;34(21-22):1145-1161. doi: 10.1089/hum.2022.068. Epub 2023 Apr 20.
5
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.4-1BB 共刺激和优化的 CD28 共刺激增强了人单特异性和双特异性第三代 CAR T 细胞的功能。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003354.
6
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2 Generation Chimeric Antigen Receptor-Modified T Cells.4-1BB 信号增强了嵌合抗原受体修饰的 CD28 整合第二代 T 细胞的抗肿瘤活性。
Front Immunol. 2020 Nov 13;11:539654. doi: 10.3389/fimmu.2020.539654. eCollection 2020.
7
A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy.基于抗原呈递树突状细胞工程化抗体外泌体的 CAR T 样平台,用于精确的实体瘤治疗。
Biomaterials. 2022 Mar;282:121424. doi: 10.1016/j.biomaterials.2022.121424. Epub 2022 Feb 18.
8
Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors.嵌合抗原受体T细胞在实体瘤过继性免疫治疗中的持久性发展
Front Oncol. 2021 Jan 6;10:574860. doi: 10.3389/fonc.2020.574860. eCollection 2020.
9
Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.不同的细胞因子和刺激条件会影响针对肿瘤抗原GD2的第三代嵌合抗原受体T细胞的扩增和免疫表型。
Cytotherapy. 2015 Apr;17(4):487-95. doi: 10.1016/j.jcyt.2014.12.002. Epub 2015 Jan 6.
10
Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.生物共轭液态固体增强了对实体瘤 - 嵌合抗原受体 T 细胞相互作用的表征。
Acta Biomater. 2023 Dec;172:466-479. doi: 10.1016/j.actbio.2023.09.042. Epub 2023 Oct 1.

引用本文的文献

1
In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.体内CAR-T细胞疗法:基于细胞的肿瘤免疫疗法的新突破。
Hum Vaccin Immunother. 2025 Dec;21(1):2558403. doi: 10.1080/21645515.2025.2558403. Epub 2025 Sep 11.
2
Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells.用于减少嵌合抗原受体T细胞制造过程中T细胞耗竭的生物功能水凝胶涂层膜。
Front Immunol. 2025 Jun 27;16:1513148. doi: 10.3389/fimmu.2025.1513148. eCollection 2025.
3
Microfluidics-Based Microcarriers for Live-Cell Delivery.

本文引用的文献

1
Chemically engineering cells for precision medicine.为精准医疗对细胞进行化学工程改造。
Chem Soc Rev. 2023 Feb 6;52(3):1068-1102. doi: 10.1039/d2cs00142j.
2
Engineering chimeric antigen receptor T cells for solid tumour therapy.工程化嵌合抗原受体 T 细胞治疗实体瘤。
Clin Transl Med. 2022 Dec;12(12):e1141. doi: 10.1002/ctm2.1141.
3
Cell delivery devices for cancer immunotherapy.用于癌症免疫治疗的细胞递送装置。
用于活细胞递送的基于微流控技术的微载体
Adv Sci (Weinh). 2025 May;12(18):e2414410. doi: 10.1002/advs.202414410. Epub 2025 Apr 4.
4
Lymph-Node Inspired Hydrogels Enhance CAR Expression and Proliferation of CAR T Cells.受淋巴结启发的水凝胶增强嵌合抗原受体(CAR)的表达及CAR T细胞的增殖
ACS Appl Mater Interfaces. 2025 Mar 19;17(11):16548-16560. doi: 10.1021/acsami.4c19942. Epub 2025 Mar 5.
5
Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung.负载STING激动剂的可吸入纳米囊泡增强了CAR-T细胞对肺部实体瘤的活性。
Nat Commun. 2025 Jan 2;16(1):262. doi: 10.1038/s41467-024-55751-4.
6
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy.体内基因编辑和嵌合抗原受体细胞的原位生成用于下一代癌症免疫疗法。
J Hematol Oncol. 2024 Nov 13;17(1):110. doi: 10.1186/s13045-024-01633-7.
7
CAR-T cell therapy in advanced thyroid cancer: from basic to clinical.嵌合抗原受体 T 细胞疗法治疗晚期甲状腺癌:从基础到临床。
Front Immunol. 2024 Jun 7;15:1411300. doi: 10.3389/fimmu.2024.1411300. eCollection 2024.
8
Lymph Node-on-Chip Technology: Cutting-Edge Advances in Immune Microenvironment Simulation.芯片上淋巴结技术:免疫微环境模拟的前沿进展
Pharmaceutics. 2024 May 16;16(5):666. doi: 10.3390/pharmaceutics16050666.
9
Epigenetics Meets CAR-T-Cell Therapy to Fight Cancer.表观遗传学与嵌合抗原受体T细胞疗法携手对抗癌症。
Cancers (Basel). 2024 May 20;16(10):1941. doi: 10.3390/cancers16101941.
10
Harboring CAR-T cells using an injectable scaffold to treat solid tumors.使用可注射支架承载嵌合抗原受体T细胞(CAR-T细胞)来治疗实体瘤。
Natl Sci Rev. 2024 Feb 28;11(5):nwae075. doi: 10.1093/nsr/nwae075. eCollection 2024 May.
J Control Release. 2023 Jan;353:875-888. doi: 10.1016/j.jconrel.2022.11.041. Epub 2022 Dec 19.
4
Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors.在瞬时可注射的刺激水凝胶龛内递送 CAR-T 细胞可改善实体瘤的治疗效果。
Sci Adv. 2022 Apr 8;8(14):eabn8264. doi: 10.1126/sciadv.abn8264.
5
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells.用于快速体内制造和释放 CAR-T 细胞的生物指令性可植入支架。
Nat Biotechnol. 2022 Aug;40(8):1250-1258. doi: 10.1038/s41587-022-01245-x. Epub 2022 Mar 24.
6
Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy.嵌合抗原受体(CAR)T细胞在实体瘤中的分散播种可增强抗癌疗效。
Natl Sci Rev. 2021 Sep 21;9(3):nwab172. doi: 10.1093/nsr/nwab172. eCollection 2022 Mar.
7
Leveraging biomaterials for enhancing T cell immunotherapy.利用生物材料增强 T 细胞免疫疗法。
J Control Release. 2022 Apr;344:272-288. doi: 10.1016/j.jconrel.2022.02.023. Epub 2022 Feb 22.
8
Dangerous dynamic duo: Lactic acid and PD-1 blockade.危险的双重奏:乳酸和 PD-1 阻断。
Cancer Cell. 2022 Feb 14;40(2):127-130. doi: 10.1016/j.ccell.2022.01.008. Epub 2022 Jan 28.
9
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.肿瘤引流淋巴结:转移和免疫的十字路口。
Sci Immunol. 2021 Sep 10;6(63):eabg3551. doi: 10.1126/sciimmunol.abg3551. Epub 2021 Sep 3.
10
Engineering enhanced CAR T-cells for improved cancer therapy.工程改造增强型嵌合抗原受体T细胞以改善癌症治疗。
Nat Cancer. 2021 Aug;2(8):780-793. doi: 10.1038/s43018-021-00241-5. Epub 2021 Aug 19.